Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.
During follow-up of leukocyte counts in 20 consecutive patients (age range 29-81 years) treated with dasatinib, 9 patients (7 chronic myeloid leukemia in chronic phase, 2 Philadelphia chromosome-positive acute lymphoid leukemia in complete remission) developed lymphocytosis (>3,000/microl). Peripheral blood smears revealed a population of large granular lymphocytes. Large granular lymphocytosis (LGL) was first noted between 1 and 8 months after initiation of dasatinib, and it has persisted up to 33 months from the onset of LGL in one patient. Peak numbers of large granular lymphocytes ranged from 2,915 to 17,425/microl. The occurrence of LGL might interfere with achieving molecular response (MR, real-time quantification of major BCR-ABL1 mRNA less than 50 copies/microg RNA) in our small cohort; 8 (89%) of 9 patients with LGL attained MR, while only 6 (55%) of 11 patients without LGL eventually achieved MR. With respect to the relationship between LGL and pleural effusion (PE), 3 (27%) of 11 patients without LGL developed PE, while 5 (56%) of 9 patients with LGL developed PE. Moreover, the mean peak number of LGL was 9,215/microl, which was much higher than the mean peak number (4,635/microl) of LGL in patients without PE. These results may suggest possible association of both events in our cohorts.
Nagata
Yasunobu
Y
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Ohashi
Kazuteru
K
Fukuda
Shiomi
S
Kamata
Noriko
N
Akiyama
Hideki
H
Sakamaki
Hisashi
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D000069439:Dasatinib; D005260:Female; D006801:Humans; D054066:Leukemia, Large Granular Lymphocytic / Q000139:chemically induced* / Q000473:pathology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008214:Lymphocytes / Q000473:pathology; D008218:Lymphocytosis / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010996:Pleural Effusion / Q000139:chemically induced* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D013844:Thiazoles / Q000009:adverse effects*
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib
Cancer. 2009 Apr 1;115(7):1381-94
19195046
Target Oncol. 2009 Apr;4(2):99-105
19381453
Blood. 2009 Aug 27;114(9):1722-3
19713476
Br J Haematol. 2008 May;141(5):745-7
18331365
Int J Hematol. 2009 May;89(4):482-488
19343480
Leukemia. 2009 Aug;23(8):1398-405
19295545
Am J Respir Crit Care Med. 2007 Oct 15;176(8):814-8
17600277
N Engl J Med. 2006 Jun 15;354(24):2531-41
16775234
Leukemia. 2009 Oct;23(10):1698-707
19474800
J Oncol Pharm Pract. 2009 Mar;15(1):17-27
18753186
J Clin Oncol. 2007 Sep 1;25(25):3908-14
17761974
Br J Haematol. 2009 Jun;145(5):581-97
19388927
Leukemia. 2008 Jun;22(6):1200-6
18401416
Cancer. 2010 Jan 15;116(2):377-86
19924787
J Med Chem. 2004 Dec 30;47(27):6658-61
15615512
Haematologica. 2009 Jan;94(1):135-9
19066329